All In MedTech

Device Trial Radar · NCT05360056

Continuous Glucose Monitoring Following Hospital Discharge

Effect of Continuous Glucose Monitoring Following Hospital Discharge of Patients With Type 2 Diabetes

Last checked: Nov 20, 2026Latest source record: Jul 21, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registry

Status

Active, not recruiting

Enrollment

108

Actual

Start

Apr 26, 2022

Primary completion

Aug 31, 2024

Study completion Jan 2027

Sponsor

Lead sponsor
Kathleen DunganAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
DexCom, Inc.
First posted
May 4, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

In this 12-week prospective observational cohort study, hospitalized insulin-requiring patients with T2D will receive a Dexcom continuous glucose monitor (CGM) to wear post-hospital discharge. Patients will complete surveys assessing patient-reported outcomes prior to CGM use and following completion of the study. CGM data will be captured by the patient smartphone app and analyzed. Patients will receive personalized CGM targets and alerts for hyperglycemia and hypoglycemia. Customized reports/ decision support will be sent to the usual diabetes provider. The initial observational cohort study design will be followed by an extension phase of 12 weeks in which data on continuation of use and glucose control will be collected but no further reports will be communicated to providers.

Conditions

  • Type 2 Diabetes

Interventions

  • DexCom G6Device

    Wearable continuous glucose monitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in TIR 70-180 mg/dlTime frame: 12 weeks
  2. % Wear Time >70%Time frame: 12 weeks
  3. DTSQc ScoreTime frame: 12 weeks

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • The Ohio State University Medical Center - Outpatient Care East

    Columbus, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.